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BIOLOGICAL DEPOSITS NECESSARY FOR PATENT PROTEC-
TION: AN EXPANSION OF PERMISSIBLE PROCEDURE-In re
Lundak, 773 F.2d 1216, 227 U.S.P.Q. (BNA) 90 (Fed. Cir. 1985).
I. INTRODUCTION
The standard for biological deposits necessary for compliance with the
enablement provisions of the Patent Act of 1952 (codified at Title 35
U.S.C.) has been altered by the Federal Circuit Court of Appeals in In re
Lundak.1 Before Lundak, patent applications dependent on the use of
biological materials2 called for the deposit of a biological sample in an
independent depository, out of the inventor's control, on or before the filing
date.3 The Lundak decision now permits an inventor to retain control of the
deposit during prosecution of the patent application, so long as the public is
guaranteed access to the invention upon issuance of a patent grant.
At first impression this modification of the deposit procedure appears to
be relatively innocuous. However, the decision inserts uncertainty and
potential for abuse into the protocol for biological deposits. The attrac-
tiveness of post-filing deposits is outweighed in most cases by the risk of
losing foreign patent protection through failure to deposit on or before
filing. In addition, the practical need to provide adequate corroborating
evidence of the chain of custody of the deposit from private hands to an
independent depository acts as a further disincentive to depositing after the
filing date.4 Thus, pre-filing deposit of the biological material remains the
safest route to sufficient disclosure of the patentable subject matter required
for attainment of both foreign and domestic protection of proprietary
rights.
1. 773 F.2d 1216, 227 U.S.P.Q. (BNA) 90 (Fed. Cir. 1985). Lundak's patent has since issued under
the designation U.S. Patent No. 4,594,325.
2. UNITED STATES PATENT AND TRADEMARK OFFICE, MANUAL OF PATENT EXAMININo PROCEDURE
§ 608.01(p) (5thed. 1983) [hereinafter MPEP] requires a deposit "[w]hen the invention depends on the
use of a microorganism which is not. . . known and readily available." See infra note 17. In practice,
the deposit requirement has been extended to cover biological materials other than microorganisms. See
infra note 3. This Note focuses on biological inventions that require a deposit, while recognizing that
some biotechnological products and processes (i.e., those that utilize biological materials that are
known or currently available to the public) do not require deposit. See infra note 7.
3. Biological materials requiring deposit include: strains of microorganisms newly isolated from
the environment; plasmids, expression vectors, viruses, microorganisms, and more complex living
cells containing recombinant DNA; mutated microorganisms or cells; and hybridomas and monoclonal
antibodies. Lundak's patent application involved an immortal mouse cell line and hybridomas. See
infra note 35.
4. See infra Part IV.A.l.b.
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II. THE DEPOSIT REQUIREMENT AND BIOLOGICAL PATENTS
A. Rationale and Purposes of a Deposit Requirement
A patent grants an inventor "the right to exclude others from making,
using, and selling the invention throughout the United States." 5 In ex-
change, the public receives an "enabling" disclosure of the invention that
allows a person who is technically familiar with the field of the invention to
"make and use the same" without undue experimentation. 6 For some
classes of biological patent applications, patent law requires deposit of a
sample of the biological material, 7 in addition to submission of a written
application. The deposit requirement ensures a quid pro quo of public
access to a biological material necessary for enablement in return for the
patent monopoly. The rationale for the deposit requirement is that patents
covering biological materials cannot be described by words alone. 8 Scien-
tific knowledge has not yet progressed to the point where living cells can be
recreated from a written description (the specification), absent necessary
starting materials. Therefore, a deposit is required to complement and
render enabling a written disclosure of a patentable microorganism or cell
line. 9
5. 35 U.S.C. § 154 (1982). A patentee receives exclusive rights to the invention for a 17-year
period.
6. 35 U.S.C. § 112, para. 1 (1982) states:
The specification shall contain a written description of the invention, and of the manner and
process of making and using it, in such full, clear, concise, and exact terms as to enable any person
skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the
same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
7. The public should not be required to reisolate or recreate the particular biological material that is
the subject matter of the patent application; therefore, with many biotechnological inventions a deposit
is required. However, if all necessary starting materials are known and readily available, a deposit may
not be required. See MPEP § 608.01(p). In addition, a deposit demonstrates that the invention was
completed at the time of filing.
The deposit requirement is thought to be supported in law by 35 U.S.C. § 114, para. 2 (1982), which
addresses models and specimens: "When the invention relates to a composition of matter, the
Commissioner may require the applicant to furnish specimens or ingredients for the purpose of
inspection or experiment." The Patent Office does not maintain depositories of its own, but rather
prescribes standards to be met by recognized, independent depositories, such as the American Type
Culture Collection or the Northern Regional Research Laboratory. The American Type Culture
Collection will be used as the prototype independent depository throughout this Note; however, other
independent depositories are recognized as sufficient to fulfill the enablement requirement of 35 U.S.C.
§ 112, para. 1 (1982).
8. Lundak, 773 F.2d at 1220, 227 U.S.P.Q. (BNA) at 93.
9. For a review of the deposit requirement generally, see Hampar, Patenting of Recombinant DNA
Technology: The Deposit Requirement, 67 J. PAT. OFF. Soc'Y 569 (1985); Meyer, Problems and Issues
in Depositing Microorganisms for Patent Purposes, 65 J. PAT. OFF. Soc'Y 455 (1983). The Patent and
Trademark Office (PTO) relies on 35 U.S.C. § 112, para. 1 (1982) to support the deposit requirement.
See MPEP § 608.01(p). Deposits have also been analogized to an "incorporation-by-reference," a
device frequently used for including outside material in the specification by reference only. Exparte
Schmidt-Kastner, 153 U.S.P.Q. (BNA) 473, 474 (PTO Bd. App. 1963).
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A deposit verifies that the invention has been reduced to practice, 10 and
eliminates any need for the public to do significant experimentation to
obtain a starting material or the patentable invention itself. Upon deposit, a
sample of the invention, or of a biological element required to make and use
the invention, is then available to the Patent and Trademark Office (PTO)
for inspection, if necessary. 11
Under the enablement requirement of 35 U.S.C. § 112, para. 1,12 the
deposit of a biological specimen in conjunction with a written specification
fulfills two purposes : (1) it provides the public and the PTO with access to
the deposit, and (2) it creates prima facie evidence that the date of invention
is the filing date of the application. 13 The procedure by which these
purposes are fulfilled has evolved over time. 14
B. Public Access to a Deposit
Originally, the deposit procedure required unrestricted public access to
all deposited material as of the filing date. 15 In re Argoudelis redefined
public accessibility in 1970.16 In Argoudelis, the inventors had deposited
on or before the filing date of the application, but had restricted public
access to the deposit during pendency of the application.
The Court of Customs and Patent Appeals held that the statutory require-
ments of section 112 were met by deposit in an independent depository that
restricted public access until after issuance of the patent. 17 The court
10. Actual reduction to practice demonstrates that an invention is operable, i.e., has been reduced
to practice. See infra notes 29-30 and accompanying text. Constructive reduction to practice means that
there is essentially no question, atfiling, that the invention is capable of being reduced to practice; it
further demonstrates that no technical problems remain to be solved, and no undue experimentation will
be required, before one skilled in the art is able to make and use the invention. See In re Argoudelis, 434
F.2d 1390, 1395, 168 U.S.P.Q. (BNA) 99, 104 (C.C.P.A. 1970) (Baldwin, J., concurring); infra notes
23-30 and accompanying text; cf note 33.
11. Inspection may be necessary, for example, if a question arises during prosecution regarding
enablement on the filing date. Access to the deposit during pendency is determined by the Commis-
sioner of the PTO in accordance with 35 U.S.C. § 122 (1982) or 37 C.FR. § 1.14(e) (1985). However,
in practice the PTO rarely, if ever, requests a sample of a deposit for inspection.
12. See supra note 6.
13. See Argoudelis, 434 F.2d at 1394-95, 168 U.S.P.Q. (BNA) at 103-04 (Baldwin, J., con-
curring).
14. See generally Note, Microorganisms and the Patent Office: To Deposit orNot to Deposit, That
Is the Question, 52 FORDHAM L. REv. 592 (1984); Note, Patent Protection for Microbiological
Processes: Has In re Argoudelis Been Mutated?, 1984 Wis. L. REv. 1679 (1984).
15. See Argoudelis, 434 F.2d at 1392, 168 U.S.P.Q. (BNA) at 101 (quoting Exparte Argoudelis,
157 U.S.P.Q. (BNA) 437, 443 (PTO Bd. App. 1966, 1967)).
16. 434 F.2d 1390, 168 U.S.P.Q. (BNA) 99 (C.C.P.A. 1970).
17. The court noted four factors relating to permanent availability of the deposited microorganism:
(1) the deposit was made in a public depository; (2) the depository was operated by a department of the
U.S. Government; (3) the depository had a contiactual obligation to place the deposit in a permanent
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reasoned that for examination purposes, the PTO could gain access to the
deposit, if necessary, through the inventor during pendency. Approval of
restricted access during pendency is only reasonable; written descriptions
of all patents are kept secret during pendency. 18 By restricting access to a
deposit before issuance, an inventor avoids giving competitors access to a
deposit during prosecution of the application. The depositor thus retains a
significant head start on deriving any patentable improvements on the
biological material. Further, restricted access prevents public disclosure
until the depositor is assured of patent protection for the invention. After
Argoudelis, an application requiring a deposit would not receive a section
112 rejection for lack of public access upon issuance unless the examiner
believed that the written disclosure plus deposit would not be enabling
when the patent issues. 19 The Argoudelis decision was subsequently incor-
porated into Patent Office guidelines for microbiological inventions. 20
The depositing procedure accepted in Argoudelis was broadened in 1975
by Feldman v. Aunstrup,21 which held that Aunstrup's restricted access
deposit of a specimen in a foreign depository met the requirements of
section 112.22 Since the restrictions on access in Feldman had been lifted at
collection, and to supply samples to persons entitled to receive them; and (4) there was no suggestion
that the deposit would change or become unusable. Id. at 1394, 168 U.S.P.Q. (BNA) at 103.
18. 35 U.S.C. § 122 (1982) states that "[aipplications for patents shall be kept in confidence...
and no information concerning the same given without authority of the applicant or owner unless
necessary to carry out the provisions of any Act of Congress or in such special circumstances as may be
determined by the Commissioner." See also 3 D. CHIsuM, PATENTS § 11.02[4] (rev. 1986).
19. See supra notes 5-9 and accompanying text.
20. MPEP § 608.01(p) contains guidelines, issued by the PTO, that set forth minimum standards
for a sufficient, enabling deposit:
(1) [T]he applicant, no later than the effective U.S. filing date of the application, has made a
deposit of a culture of the microorganism in a depository affording permanence of the deposit and
ready accesibility [sic] thereto by the public if a patent is granted, under conditions which assure
(a) that access to the culture will be available during pendency of the patent application to one
determined by the Commissioner to be entitled thereto under 37 C.F.R. § 1.14 and 35 U.S.C.
§ 122, and (b) that all restrictions on the availability to the public of the culture so deposited will be
irrevocably removed upon the granting of the patent;
(2) such deposit is referred to in the body of the specification as filed and is identified by deposit
number, name and address of the depository, and the taxonomic description to the extent available
is included in the specification; and
(3) the applicant or his assigns has provided assurance of permanent availability of the culture to
the public through a depository meeting the requirements of (1). Such assurance may be in the form
of an averment under oath or by declaration by the applicant to this effect.
21. 517 F.2d 1351, 186 U.S.P.Q. (BNA) 108 (C.C.P.A. 1975), cert. denied, 424 U.S. 912, 188
U.S.P.Q. (BNA) 720 (1976).
22. The four factors enumerated in Argoudelis were interpreted to be sufficient, but not mandatory,
for an enabling deposit. See Feldman, 517 F.2d at 1355, 186 U.S.P.Q. (BNA) at 112. In particular, the
Feldman court held that use of a private depository not operated by the United States Government, and
not operated within the United States was enabling. See id. at 1356, 186 U.S.P.Q. (BNA) at 113; see also
supra note 17.
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the time of decision, public access upon issuance was assured. As in
Argoudelis, the PTO could obtain access during pendency through the
inventor, and deposit at the time of filing was held to constitute reduction to
practice. 23 Thus, after Feldman, use of either foreign or domestic indepen-
dent depositories adequately fulfilled the enablement requirement of sec-
tion 112.
C. The Doctrine of Constructive Reduction to Practice
The second aspect of the enablement requirement of 35 U.S.C. § 112,
para. 1 establishes the filing date of a patent application as the prima facie
date of invention. 24 The doctrine of constructive reduction to practice
applies to inventions that have not been successfully made or carried out on
or before the filing date, but that could be reduced to practice on the filing
date.25
If two or more inventors develop similar inventions very close in time,
the inventor that first reduces the invention to practice is entitled to
priority.26 In determining priority of invention, three elements are consid-
ered: (1) date of conception (mental discovery of the means and ends of the
invention); (2) date of reduction to practice; and (3) reasonable diligence by
the inventor, from the date of conception to the date of reduction to
practice, in perfecting the invention and pursuing a patent. 27 The date of
reduction to practice becomes significant if an inventor needs to prove
priority of invention. 28
Demonstration of reduction to practice of an invention verifies that a
product or process has been, or could be, made or performed successfully
23. Feldman, 517 F.2d at 1354-55, 186 U.S.P.Q. (BNA) at 112-13. On the filing date, Aunstrup's
invention was "fullycapableofbeingreducedtopractice. . . [and] the second function of§ 112, first
paragraph-that of establishing the application filing date as the prima facie date of invention-was
satisfied by Aunstrup's specification." Id. at 1355, 168 U.S.P.Q. (BNA) at 113.
24. See supra notes 13, 23 and accompanying text.
25. See infra notes 26-32 and accompanying text.
26. See 3 D. CtnsuM, PATENTS § 10.01 (rev. 1986). Two exceptions to this general rule should be
noted: (1) an inventor who is the first to conceive the invention, but the last to reduce it to practice, may
get priority upon a demonstration of reasonable diligence in reducing the invention to practice that
began before the first reduction to practice; and (2) the first to reduce to practice cannot get priority if the
invention is abandoned, suppressed, or concealed. Id.
27. See 35 U.S.C. § 102(g) (codifying prior decisional law). See generally 3 D. CHISUM, PArENrS
§ 10.03[1] (rev. 1986).
28. Priority rules focus on conception, actual reduction to practice, and constructive reduction to
practice, in that order. In contrast, proof of priority emphasizes the same elements in reverse order
(constructive reduction to practice, actual reduction to practice, conception). See 3 D. CtnsuM, PATErs
§ 10.03[l][c] (rev. 1986). For example, an inventor might have to prove an earlier date of actual
reduction to practice or an earlier date of conception to establish priority over another inventor. See also
infra notes 29-32 and accompanying text.
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on or before the filing date of the application. 29 The doctrine of constructive
reduction to practice is based on two premises: (1) actual reduction to
practice is unnecessary to issuance of a valid patent (i.e., while the
invention is still just an idea, it is perfectly capable of working and so is no
less an invention); and (2) as a matter of law, the date of filing should be
taken as the date of reduction to practice.30
If the disclosure of the patent application meets the requirements of 35
U.S.C. § 112, para. 1, for every type of patent the filing date constitutes a
constructive reduction to practice.31 The inventor is entitled to use the filing
date as the date of reduction to practice for priority and patentability
purposes, even though the invention may not be actually reduced to
practice, because the application as filed allows another to practice the
invention. In contrast, an applicant demonstrates actual reduction to prac-
tice of the invention when a described process is performed or a product is
synthesized; the invention is thus proven operable. 32
In the context of patent applications covering biological compositions of
matter, deposits are tangible evidence of an invention (a product) actually
reduced to practice. By requiring a deposit upon application, the filing date
represents the latest date of actual reduction to practice of the biological
material, 33 as well as the date of constructive reduction to practice imposed
by patent law.
In summary, before Lundak and for applications requiring a deposit,
disclosures were considered enabling under 35 U.S.C. § 112, para. 1 if:
(1) the PTO or authorized third parties 34 could gain access to the deposit
during pendency of the patent application (restricted public access permit-
ted); (2) the public was assured of access to the deposit upon issuance of the
patent; and (3) the deposit was placed in an independent depository, out of
the inventor's hands, on or before the filing date, to fulfill the reduction to
practice requirement. Lundak represents a clear departure from the require-
ment for transfer to an independent depository by the filing date in order to
satisfy the enablement requirement of 35 U.S.C. § 112, para. 1.
29. Under 35 U.S.C. § 101 (1982), patentable inventions include "any new and useful process,
machine, manufacture, or composition of matter." However, this Note deals exclusively with products
and processes, the types of inventions most commonly arising in biotechnology patent applications.
30. See 3 D. CHISUM, PATENTS § 10.05[2] (rev. 1986). The second premise avoids the difficulty of
demonstrating an earlier reduction to practice in most cases. However, where junior and senior
applicants are claiming priority, either applicant may establish an earlier date of invention by demon-
strating earliest reduction to practice through proper supporting evidence.
31. See 3 D. CHtSUM, PATENTS § 10.05[1] (rev. 1986).
32. See id. § 10.06.
33. The possibility that a deposited sample may not be actually reduced to practice cannot be ruled
out, since actual reduction to practice requires not only making the invention, but also testing it for its
desired results.
34. See supra note 11.
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III. THE LUNDAK DECISION
A. Facts
Lundak sought patent protection for a cell line useful for the production
of monoclonal antibodies. 35 This claim was unquestionably of a type
requiring a deposit. 36 Through inadvertence, Lundak's application was
filed approximately one week before the cell line was deposited with the
American Type Culture Collection (ATCC), a recognized PTO deposi-
tory.37 Prior to and after filing, Lundak maintained his cell line in his own
laboratory at the University of California, and in the laboratories of
colleagues at that university and elsewhere. 38 Lundak subsequently depos-
ited the cell line with ATCC approximately one week after filing. The
examiner rejected Lundak's claims under section 112 for non-enablement,
due to the late deposit. In response, Lundak embarked on a series of legal
challenges, culminating in a Court of Appeals for the Federal Circuit
(Federal Circuit)39 opinion that modified the deposit requirements under 35
U.S.C. § 112, para. 1.
B. Board Decision
Following the Patent Office examiner's final rejection of the claims,
Lundak petitioned the Commissioner of Patents, requesting a post-dating
of his application to the date of deposit. The Commissioner denied the
petition, in the belief that the application was complete for purposes of
assigning a filing date.40
35. Lundak's claims encompassed (1) an immortal human B-cell line and (2) a hybridoma
produced from the fusion of an immune lymphocyte and such immortal B-cell. The immortal cell line
was obtained through a process of mutagenesis and selection. For a general description of hybridoma
techniques and monoclonal antibodies, see Milstein, MonoclonalAntibodies, 243 Sci. AM. 66 (1980).
36. The entire series of Lundak opinions refer only to deposit of the immortal cell line of the first
claim, but do not refer to the hybridoma of the second claim, which results from "the fusion of an
immunized lymphocyte and a cell line according to Claim 1." Lundak, 773 F.2d at 1218,227 U.S.P.Q.
(BNA) at 91. Immunized lymphocytes are well-known, and since the cell line of claim 1 required
deposit, all necessary starting materials for constructing a hybridoma according to the second claim
were known and readily available. See supra note 2. Thus, no additional deposit was needed for
enablement of claim 2.
37. See supra note 7.
38. Lundak, 773 F.2d at 1219, 227 U.S.P.Q. (BNA) at 92.
39. The Federal Circuit was created by a 1982 Act of Congress, so that all patent cases would be
adjudicated by one court of appeals. Congress intended to provide uniformity and stability to appellate
patent decisions. The Federal Circuit came into existence on October 1, 1982, and is bound by the
precedent of the Court of Customs and Patent Appeals.
40. After denial of his petition by the Commissioner, Lundak brought a mandamus action in the
Federal Circuit regarding the Commissioner's refusal to post-date his application. The mandamus
action was consolidated into the instant appeal of the examiner's section 112 rejection for non-
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Lundak then appealed the examiner's 35 U.S.C. § 112, para. 1 final
rejection to the PTO Board of Appeals, 41 arguing that deposit after filing,
but before issuance, met the requirements for enablement. The Board of
Appeals en banc held the deposit inadequate for enablement at filing.
42
Argoudelis and Feldman were distinguished by the Board, because both
involved deposits made before or on the filing date.43
Although Lundak's cell line was in both his own and his colleagues'
hands on the filing date, the Board held that this manner of "deposit" did
not guarantee the reliability of maintenance, permanence, or accessibility,
as would be provided by a "recognized" depository.44 The Board further
stated that the later deposit was prohibited by the "new matter" provision of
35 U.S.C. § 132, 45 which precludes addition of new matter to the specifi-
cation after filing of the application. 46 However, six of the eighteen Board
members would have allowed Lundak to supplement the record to prove
chain of custody from his laboratory to ATCC deposit. 47
enablement, since both actions arose from a common factual situation. See Lundak, 773 F.2d at 1220,
227 U.S.P.Q. (BNA) at 93.
41. Exparte Lundak, No. 588-11 (PTO Bd. App. Aug. 21, 1984).
42. The en banc panel is indicative of the perceived importance of the case within the PTO. Twelve
members believed that Lundak had filed an inadequate disclosure; that is, that someone skilled in the art
could not make and use the invention. In addition, Lundak did not provide evidence that the cell line was
generally known or available through any reasonable source. Ex parte Lundak, slip op. at 9. Two
members found evidentiary deficiencies in Lundak's chain of custody from his laboratory to the ATCC,
but would have permitted Lundak to prove chain of custody by either (1) filing a continuation application
and supplementing the record, or (2) petitioning the Commissioner to reopen the prosecution and then
supplementing. A continuation is a second application for the same invention, and may be used to
establish a right to further examination by the primary examiner. See 35 U.S.C. § 120(1982); 37 C.F.R.
§§ 1.60, 1.78 (1985); see also Ex parte Lundak, slip op. at 16-17 (McKelvey, concurring). Four
members considered their concurrence to constitute a new ground of rejection; under 37 C.F.R.
§ 1.196(b) (1985), Lundak could have introduced proper declarations or affidavits to prove sufficient
maintenance and chain of custody to overcome the § 112 rejection. SeeExparte Lundak, slip op. at 24
(Rzucidlo, concurring).
43. See Exparte Lundak, slip op. at 7-8.
44. See id. at 6 n.*, 7.
45. According to 35 U.S.C. § 132 (1982), '[n]o amendment shall introduce new matter into the
disclosure of the invention."
46. The present practice of many inventors is to deposit at the time of filing, fulfilling the
pre-Lundak guidelines for deposit. An application requiring a deposit often contains reference to a
timely ATCC deposit (for example, "ATCC Accession No. "), and the specific accession
number assigned by the ATCC after receipt of the deposit is added later by amendment.
The Board believed that Lundak's 20-year contractual arrangement with ATCC left open the real
possibility that the deposit could become non-enabling before termination of the patent monopoly. At
the time of reconsideration by the Board, Lundak had extended the ATCC contract. However, to
overcome non-enablement Lundak needed to show more than being in position to provide an enabling
disclosure (i.e., deposit) at some time in the future.
47. See supra note 42.
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C. Federal Circuit Opinion
Lundak appealed to the Federal Circuit, which reversed the section 112
rejection of Lundak's application for non-enablement due to deposit after
filing.48 The court found no controlling distinction between PTO access to
Argoudelis' restricted domestic deposit, Aunstrup's restricted foreign de-
posit in Feldman, and Lundak's private deposit at the University of Califor-
nia.49 The Lundak decision thus eliminated the prior mandatory transfer of
a physical specimen of the invention to an independent depository on or
before the filing date.50 Although theLundak court did not explicitly have to
address the question of timing of transfer to an independent depository,
because it had been mooted, 51 the opinion suggested that such transfer must
be made some time prior to issuance of the patent.52
In response to the PTO's argument that a post-filing deposit should be
barred as new matter, the court analogized Lundak's deposit one week after
filing to material incorporated-by-reference inIn reHawkins.53 In Hawkins,
the inventor had inserted textual material from cross-referenced, co-pending
British patent applications into his United States application after the initial
filing date. The Hawkins court held that this did not constitute addition of
new matter.54 The Lundak court relied directly on Hawkins, and distin-
guished White Consolidated Industries, Inc. v. Vega Servo-Control, Inc., 55
wherein an applicant did not disclose an essential trade secret56 either during
pendency or after issuance.57
48. See supra note 40.
49. See Lundak, 773 F.2d at 1222, 227 U.S.P.Q. (BNA) at 94.
50. In Lundak's case, public access after issuance was no longer in doubt, because he haddeposited
with the ATCC during pendency and before PTO prosecution.
51. See supra note 50.
52. At present, prosecution of a biotechnology patent application may take as long as two to three
years, suggesting that the applicant would have this extended period of time in which to deposit.
53. 486 F.2d 569, 179 U.S.P.Q. (BNA) 157 (C.C.P.A. 1973).
54. Hawkins, 486 F.2d at 575, 179 U.S.P.Q. (BNA) at 162.
55. 713 F.2d 788,218 U.S.P.Q. (BNA) 961 (Fed: Cir. 1983).
56. A trade secret may require elaborate precautions to keep an invention from becoming public
knowledge. Once the secret is revealed to an unauthorized person, the invention may become accessible
to the public, with no return for the inventor or owner of the trade secret. In contrast to patent protection,
which is based on a policy of public disclosure of an invention, for trade secret protection an inventor
must maintain absolute control of the secret, keeping it from those not entitled to receive the
information. Further, enforcement of trade secrets is expensive and difficult. See generally WASH. REv.
CODE ch. 19.108 (1985) (Uniform Trade Secrets Act); RESTATEmENT (FrsT) OF TORTS § 757 (1939).
57. In White Consolidated, the application containing the trade secret was non-enabling as filed.
Since no attempt was made to insert the trade secret information, the question of new matter was not
addressed. In contrasttoHawkins' previously filed foreign patent applications, Lundak made reference in
his specification to an intended ATCC deposit. On its facts, Lundak appears to be distinguishable from
1527
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The Federal Circuit concluded that it was immaterial whether Lundak's
cell line was in his hands, the hands of colleagues, or in the hands of an
independent depository as of filing. The court believed that an accession
number 58 and deposit date would not enlarge or limit the disclosure of the
invention. Further, this was not the type of new matter that 35 U.S.C. § 132
was designed to guard against. 59 The court believed that the disclosure as
filed satisfied the requirement for reduction to practice as of filing, since the
PTO had conceded that the cell line was in Lundak's possession at the time
of filing. 60
The court then addressed the PTO's argument that the deposit procedure
approved in Lundak would facilitate filing of sham applications. In a brief
dismissal of that possibility, the Federal Circuit stated that any post-Lundak
procedural change should not alter the risk or frequency of sham applica-
tions.61 The court asserted that the examiner has always relied on the
inventor's documentation, 62 thereby implying that the pre-Lundak protocol
was just as uncontrolled and subject to abuse as a procedure permitting
deposit after the filing date.
In what may have been an apparent effort to avoid working a perceived
injustice against Lundak, the Federal Circuit reversed the PTO Board of
Appeals. 63 The court thus eliminated the former bright line rule requiring a
Hawkins, because unlike Hawkins' British applications on file with an independent agency, Lundak's cell
line was not already "on file" in an independent depository. Thus, deposit in university laboratories at
filing more closely resembles the trade secret of White Consolidated. The court nevertheless concluded
that Lundak's reference to intended ATCC deposit was sufficient to avoid a new matter prohibition.
58. A unique accession number is assigned to a deposit upon receipt by an independent depository.
The accession number identifies the deposit for the depository and for individuals who wish to order
samples of the deposit once it becomes publicly available.
59. Lundak, 773 F.2d at 1223, 227 U.S.P.Q. (BNA) at 96.
60. See Exparte Lundak, No. 588-11, slip op. at 15 (PTO Bd. App. Aug. 21, 1984) (McKelvey,
concurring).
61. See Lundak, 773 F.2d at 1223-24, 227 U.S.P.Q. (BNA) at 96.
62. Id. at 1224, 227 U.S.P.Q. (BNA) at 96.
63. In retrospect, several alternatives were available to Lundak or the Federal Circuit which might
have provided relief for Lundak's predicament. Prompt filing of a continuation-in-part (CIP) applica-
tion would have allowed Lundak to add a reference to the late deposit in the specification. Ordinarily, a
CIP filed anytime during pendency may use material in the parent application to overcome a reference,
or to support priority in an interference action. However, Lundak would have received no benefit from
the filing date of the parent application, because the parent was non-enabling as filed. Since Lundak did
not promptly file a CIP, thereby securing a filing date that was only days or weeks after the original
erroneous filing, the apparent harsh result that would have resulted from denying Lundak's appeal could
have been attributed to his own failure to mitigate potential damages by CIP submission.
The court might also have attempted to narrow the Lundak decision by permitting a deposit one week
after the filing date, when supported by sufficient corroboration of a chain of custody, but only in cases
where an applicant demonstrates reasonable diligence in transferring a sample to an independent
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deposit that is out of the inventor's hands and in an independent depository
as of the filing date to satisfy the enablement requirement of section 112.
IV. ANALYSIS
A. Consequences Stemming from Elimination of the Pre-Lundak Bright
Line Deposit Rule
After the Lundak decision, applications encompassing biotechnological
inventions no longer need to be accompanied by deposit on or before the
filing date. Elimination of this requirement fosters uncertainty in the patent
application process, because corroborating evidence offered as proof of
reduction to practice as of the filing date must now be evaluated on a case by
case basis. In addition, the decision increases the potential for filing of
sham applications, and is incompatible with foreign patent requirements.
1. Uncertainty in the Application Procedure
a. Surrender of Objectivity with Approval of Post-Filing Deposit
The Lundak decision has injected uncertainty into the deposit procedure,
where before there was certainty.64 The Federal Circuit has receded from
the pre-Lundak "bright line," objective determination of constructive/
actual reduction to practice for biotechnological inventions. Instead, the
PTO has been launched onto a "slippery slope" determination of whether
the filing date in each case of late deposit in fact represents the date of
depository. Although a determination of reasonable diligence would not be as finite as the "bright line"
in existence before Lundak, at least the necessary transfer would be made sometime early in the
pendency period, rather than allowing transfer immediately prior to issuance of a biological patent.
The Federal Circuit might have elected to post-date Lundak's application to the date of deposit, as
Lundak originally requested. However, the Federal Circuit may have been reluctant to directly post-date
when a mechanism for indirectly post-dating applications, filing of a CIP, was already in place. Further,
post-dating could place an administrative burden on the PTO. By withholding assignment of a filing
date until both the written application and the deposit have been submitted, the court could have given
an inventor significant impetus to deposit as quickly as possible after the written materials had been
submitted, in order to obtain the earliest possible filing date. (A later filing date might preclude
avoidance of a prior art reference or be fatal to a favorable interference decision.) In contrast, the course
chosen by the Federal Circuit encourages postponement of ATCC deposit for as long as possible.
64. Although the expanded Board of Appeals differed as to which of the dual purposes of 35
U.S.C. § 112, para. 1 (1982) (public access on issuance orconstructive reductionto practice as of filing)
was not met by Lundak's late deposit, the Federal Circuit considered the question of public access to be
mooted by Lundak's ATCC deposit one week after filing. The court's opinion therefore focused on the
aspect of constructive reduction to practice. See supra notes 26-32 and accompanying text.
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invention. While the Lundak decision does offer certain benefits to inven-
tors, 65 any benefits derived from case by case adjudication are outweighed
by the sacrifice of certainty.66
Before Lundak, the biotechnological applicant had to make an objective
showing of reduction to practice (possession of the biological material) by
means of a written disclosure with deposit on or before the filing date, in
cases where a deposit was required. By permitting post-filing deposits, any
showing of reduction to practice by a late depositor must now be subjec-
tively reviewed on an individual basis by the PTO. The late depositor will
need to present adequate corroborating evidence that, as of the filing date,
the biological material was in the inventor's hands, and that the same
biological material has been deposited with an independent depository, in
order to obtain the benefit of the filing date. 67 If the PTO determines that
deposit of a biological material is necessary for enablement, and that the
invention was not reduced to practice as of the filing date, the patent will be
denied on the grounds of non-enablement. While it is unclear what type and
amount of corroborating evidence will suffice to prove enablement as of the
filing date, the practical importance of the standard for corroborating
evidence is immense.
b. Corroborating Evidence
The Lundak decision permits an applicant to submit a necessary deposit
after the filing date of the written application. In order to guarantee actual/
constructive reduction to practice on or before the filing date, late deposits
will require corroborating evidence of the chain of custody from private
depositories to the ATCC. The PTO has not yet established the standard for
such corroborating evidence. 68 The PTO Board of Appeals recently applied
65. See infra note 71 and accompanying text.
66. Bright lines in patent law assist competitors and courts in objectively determining the bounds of
patent protection, and indicate to applicants the proper conduct necessary to obtain the broadest scope
of protection. Prior to Lundak, determination of whether a deposit evidenced reduction to practice as of
the filing date was straightforward. If the biological material was placed in an independent depository
on or before the filing date, the deposit was presumed to demonstrate actual and constructive reduction
to practice, and to be sufficient for an enabling disclosure. After Lundak, a late depositor will continue
to receive a presumption of actual and constructive reduction to practice as of the filing date, but
enablement on the filing date must be affirmatively established by adequate corroborating evidence of
the chain of custody of the deposit.
67. For biological patents, this will require a showing of actual reduction to practice of the
deposited material as of the filing date. See supra notes 26-34 and accompanying text (Part II.C.).
68. The PTO has recently issued draft policy guidelines for deposit of biological materials. Pat.
Trademark & Copyright J. (BNA) No. 32, at 90 (May 22, 1986) [hereinafter Draft Guidelines]. These
guidelines require a corroborating statement, but do not detail how much or what kind of evidence will
be sufficient.
By analogy to case law on adequacy of corroboration in patent interferences, certain elements may
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Lundak in Ex parte Old,69 a case involving private deposit in a research
institute. However, in Old, the Board did not have to address the standard
for corroborating evidence required to prove chain of custody, because the
deposit had not been transferred from the Sloan-Kettering Institute for
Cancer Research to an independent depository. 70 Corroborating evidence
was not reviewed in Old, so a biotechnological inventor still faces reason-
able uncertainty as to what standard of corroborating evidence might be
applied in instances of post-filing deposit of biological materials.
Case by case evaluation of corroborating evidence will also significantly
affect the PTO itself. Federal Circuit approval of deposition after filing will
lead, in practice, to an increased amount of paperwork and time for
reviewing corroborating evidence on a case by case basis. In turn, the
workload of examiners will be increased, and longer time periods from
filing to issuance will likely result. Logically, for post-filing depositors,
more extensive corroborating evidence may be required with increasing
time periods from filing date to ATCC deposit date.
An advantage gained by inventors by postponing deposit is elimination
of the cost and effort of depositing with an independent depository before
receiving assurance that a patent will issue.71 However, inventors who
not be required: (1) that the corroboration be present in a single affidavit; (2) that one of the affiants saw
the inventor prepare the new microorganism or cell line; and (3) that the affiant understood the
significance of the experiment. See Berges v. Gottstein, 618 F.2d 771, 205 U.S.P.Q. (BNA) 691
(C.C.P.A. 1980). Factors favorable to a finding of sufficient corroboration include: a highly organized
and routinely practiced procedure for identifying, preserving, and testing new strains or cell lines;
results of independent testing; absence of contradiction and internal conflict in the evidence; and
difficulty in fabricating results. Id. at 774-75, 205 U.S.P.Q. (BNA) at 694-95. While it is no longer
necessary to prove in detail an unbroken chain of custody in patent interference actions, the requirement
for some evidence of independent corroboration, beyond the inventor's testimony, has not been
omitted. Since it is uncertain how strict the standard for corroboration of deposits will be, the safest
approach would be to document and witness every transfer and storage step leading to actual reduction
to practice.
69. 229 U.S.P.Q. (BNA) 196 (PTO Bd. App. 1985).
70. As in Lundak, Old resulted in reversal of a section 112 rejection for non-enablement. The
applicants in Old filed declarations that several hybridoma cell lines had been deposited prior to the
filing date at Sloan-Kettering Institute for Cancer Research, asserting that the maintenance practiced at
Sloan-Kettering is substantially the same as that practiced by the ATCC. However, in contrast to
Lundak, the applicants stated that they had no intent to transfer the deposits to the ATCC until after
receipt of a notice of allowance.
The Board interpreted Old in light of Lundak, and was similarly convinced that the applicants had
demonstrated reduction to practice prior to filing. In addition, public access to the invention was
believed assured by the "renown and integrity" of Sloan-Kettering and its professed maintenance
procedures. Old, 229 U.S.P.Q. (BNA) at 199. The PTO Board of Appeals apparently read Lundak as
approving private deposit until notice of allowance was sent. The difficulty presented by this reading is
that the type and quantity of corroborating evidence required to support storage in private depositories
remains an unknown parameter.
71. At the time this Note was prepared, the costs for depositing with ATCC in compliance with
international requirements, for example, include: $570 for storage and maintenance for 30 years plus 5
years after the most recent request for a sample of the deposit; $100 for viability testing (optional); $300
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choose to exercise the option to deposit after filing are exchanging the ease
and certainty that was provided by a pre-filing enabling deposit for the
unpredictability of case by case analysis that accompanies post-filing
deposits. 72 If a late depositor's corroborating evidence is found to be
insufficient, the section 112 rejection for non-enablement will stand and no
patent will issue.
2. Potential for Sham
The Federal Circuit discounted any increased potential for sham applica-
tions in the wake of Lundak.73 A distinct possibility, however, is that
Lundak might open the door for deposit of improved or switched samples
during pendency, rather than deposit of the sample in the inventor's hands
at filing. This consequence may arise after Lundak because the deposit can
remain solely in the applicant's hands up to the time the patent issues. 74
If a new or improved biological sample is deposited after the filing date,
the deposit adds new information to the specification and would be barred
as new matter under 35 U.S.C. § 132. 75 Deposit in independent domestic
or foreign depositories as of the filing date circumvented any temptation to
stretch the definition of what was "in the inventor's hands at filing" because
compliance with the pre-Lundak procedure meant that the deposit was out
for notification to depositors of recipients of a deposit for 30 years (optional); and $10 for immediate
notification of the assigned ATCC accession number (optional). See ATCC Form 34, reprinted in Patent
Practitioner's Guide to Deposition and Depositories Worldwide, AIPLA Chemical Practice Comm.,
Biotechnology Subcomm., Statistics Section (Jan., 1985). In addition, beforeLundak the inventormay
have made multiple deposits to cover all possible PTO enablement requirements; i.e., starting mate-
rials, end products, and expression vectors. Thus, for institutional applicants who file numerous
biological patent applications each year, depositing can become very costly, particularly because
payment is made in advance, before receipt of assurance that the patent will issue.
72. The eventual result of extended time for deposit and uncertainty arising from case by case
adjudication might lead to pursuit of trade secret protection instead of patent protection for bio-
technology inventions, in a manner analogous to computer software protection.
73 See supra notes 61-62 and accompanying text.
74. Pre-Lundak procedures entailed a matching of the strain or cell line described in the specifica-
tion to a specific deposit; improved strains or cell lines could not be added because they would be barred
as new matter under 35 U.S.C. § 132 (1982). However, it should be noted that, before Lundak,
independent depositories did not examine or characterize materials deposited with them, either for
viability or content. After Lundak, the inventor conceivably could later deposit a biological material
that was not in the inventor's hands on the filing date, if the biological material was adequately
described in the written specification. The Lundak decision might encourage filing of applications for
inventions conceived, but not actually or constructively reduced to practice, in order to obtain a United
States priority date. In actuality, however, any material reduced to practice after the filing date may be
difficult, if not impossible, to identify as the biological material that was in the inventor's hands on the
filing date. Further, most inventors would not risk potential loss of patent rights due to insufficient
evidence of reduction to practice on the filing date.
75. New matter may include the addition of inherent characteristics, such as chemical or physical
properties, a new structural formula, or a new use. MPEP § 608.04(a) (relying on 37 C.F.R. § 1.118
(1985)).
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of the inventor's hands at filing. A procedure that opens the door to fraud on
the PTO may lead to abuse, especially in light of increasing commercial
and financial pressures placed on biological inventors and enterprises to
obtain patent protection for technology developed in the laboratory.76
3. International Implications/Complications
Foreign patent protection for an invention dependent on a new or
unavailable biological material may be precluded by the depositing pro-
cedure accepted in Lundak.77 The Federal Circuit decision provides a
liberal deposit procedure sufficient for receipt of United States patent
protection, but the court did not address potential problems in obtaining
foreign patent protection.
Although independent deposit by an inventor after the filing date, when
accompanied by sufficient corroboration of the chain of custody, will now
allow enablement of domestic patent applications, foreign filing pro-
cedures that require the pre-Lundak protocol of deposit on or before the
filing date will not be met by post-filing deposits. 78 Accordingly, if an
applicant for a domestic patent perceives any possibility that foreign patent
protection might be sought, the required domestic biological deposit
should still be made according to the pre-Lundak procedure. Inventors
might not elect to follow the more liberal deposit procedures permitted by
Lundak, in the realization that by taking advantage of such procedures they
may be sacrificing potential world-wide patent protection. Commercial
realities may therefore limit the practical impact of the Lundak decision.
Additionally, the door has been opened for some foreign applicants to
obtain domestic patent protection for inventions where foreign patents were
76. Sanctions resulting from fraud on the PTO are discussed at 4 D. CIsUM, PATENTS § 19.03[6]
(rev. 1986). Proof of fraud may result in removal of a patent application from PTO files, or in invalidity
or unenforceability of a patent.
77. Issuance of a domestic patent only grants patent rights enforceable in the United States. To
exclude others from making, using, and selling the invention outside the United States, foreign patent
protection must be obtained.
78. Although international policy supports uniformity in patent laws, international deposit require-
ments are determined by national laws. The European Patent Convention (EPC), consisting of 11
countries, requires a deposit on or before the filing date of the application. See EPC Rule 28, reprinted
in R. CREsPI, PATENTING IN THE BIOLOGiCAL ScINCEs, 203-06 app. (1982). See generally Comment,
Patenting Microorganisms: Working the Bugs Out of the International Depositary Authority, 14 CAL.
W. INT'L L.J. 49 (1984). The Budapest Treaty on the International Recognition of the Deposit of
Microorganisms for the Purposes of Patent Procedure, Apr. 28, 1977, T.I.A.S. No. 9768, reprinted in 6
D. CHisUM, PATENTS app. 22 (rev. 1986) [hereinafter Budapest Treaty], recognizes deposits made with
any International Depositary Authority. According to article 3, no party to the treaty can impose
requirements additional to or different from those provided by the Budapest Treaty. Budapest Treaty
signatories include: the Federal Republic of Germany, France, Japan, the Soviet Union, the United
Kingdom, the United States, and 13 other countries.
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not available because of deposit after filing. A foreign inventor who
inadvertently or intentionally deposited after filing might now use a foreign
filing date for domestic priority, if the domestic application is filed within a
year of foreign filing. 79
Finally, the Lundak decision makes the determination of international
priority dates of filing much less clear. After Lundak, a late deposit is not
barred as new matter, and therefore the filing date of the application is the
domestic priority date. Although at present a domestic patent application
accompanied by a post-filing deposit would preclude use of a United States
filing date as a priority date for foreign patent applications, several options
might arise. Under one option, in cases of post-filing deposit, foreign filing
procedures might assign a priority date of the date of deposit, rather than of
the domestic filing date. Second, foreign patent authorities might defer to
the domestic patent priority date, and grant that date priority for foreign
purposes. 80 Third, foreign filing procedures might be amended to conform
with the Lundak decision, for achievement of deposit uniformity through-
out the world. At present it remains unknown which, if any, of these results
will follow from Lundak.
B. Future of the Deposit Requirement
Although Lundak permits a liberalized deposit procedure, an applicant
can avoid submission of corroborating evidence documenting the chain of
custody of the deposit by continuing to satisfy the pre-Lundak require-
ments. Fulfilling pre-Lundak requirements eliminates the uncertainty and
the associated risk of insufficient corroboration. In addition, the temptation
to assert in the future that later improvements were known at the time of
filing would thereby be avoided. Finally, compliance with foreign patenting
requirements may be ensured by depositing on or before the filing date.
Therefore, the potential hazards associated with post-filing deposits would
appear to outweigh the monetary and practical benefits that may be derived
by postponing deposit with an independent depository.
By depositing after the filing date of the application, an applicant loses a
presumption of enablement that accrued under the pre-Lundak depositing
procedure. After Lundak, an applicant who chooses to deposit after the
filing date must take active steps to establish enablement as of the filing
date. In contrast, a deposit on or before the filing date gives rise to a
79. 35 U.S.C. § 119 (1982) describes in more detail the effect of an earlier foreign filing date on a
U.S. patent application filed within 12 months from the earliest such foreign application.
80. However, in the reverse circumstance, the United States will not give an applicant benefit from
foreign priority documents unless the foreign application complies with the requirements of United
States patent law. See 3 D. CHISUM, PATENTS § 14.03[3] n.19 (rev. 1986).
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presumption of enablement, which may be overcome only by a prima facie
showing to the contrary.
The Lundak court granted the late depositor benefit of the filing date only
after concluding that Lundak's written specification, plus corroborating
evidence of actual reduction to practice, sufficed to meet the section 112
requirement for enablement. 81 Lundak thus received a presumption (and
the benefit) of a priority date as of filing, because he was able to demon-
strate that he had actually reduced the invention to practice as of the filing
date. The possibility of mere constructive reduction to practice as of the
filing date for any biotechnological patent application that currently re-
quires an accompanying deposit apparently continues to be foreclosed after
the Lundak decision.
The deposit requirement assures that a particular end product may be
reproducibly obtained. However, in light of rapid advances in bio-
technology, commentators currently debate whether a deposit is indeed
necessary in every case of biotechnological invention. 82 If certain types of
patentable subject matter are relieved of the deposit requirement, con-
structive reduction to practice of biotechnological inventions could con-
ceivably occur. 83 At present the deposit procedure for biological materials
has been modified, and in the future deposits may even be eliminated for
81. Although Lundak did not deposit in an independent depository on or before the filing date,
Lundak's 10 pages of written description were held to be more than adequate to demonstrate reduction
to practice (possession of the invention), even in the absence of a prefiling deposit. Reduction to practice
was further supported with declarations by the inventor and his colleagues, filed during the period
between the Board decision and argument before the Federal Circuit, that the cell line was in their hands
at filing and was the same as the sample deposited one week later with ATCC.
Although a hybridoma, according to Lundak's second claim, may not have been actually reduced to
practice on the filing date, the hybridoma is a type of biological material that did not require deposit,
and thus might be constructively reduced to practice. See supra note 36. However, the PTO Board of
Appeals discussion in Old, directed to hybridomas and obviousness, suggests that hybridomas may not
be amenable to constructive reduction to practice. See Old, 229 U.S.P.Q. (BNA) at 200.
82. The argument hinges as much on technical as on legal issues. See Hampar, Patenting of
RecombinantDNA Technology: TheDepositRequirement, 67 J. PAT. OFF. Soc'y 569 (1985); Comment,
Microorganisms and the Patent Office: To Deposit orNot to Deposit, That Is the Question, 52 FORDHAM
L. REv. 592 (1984); Note, Patent Protection forMicrobiological Processes: Has In re Argoudelis Been
Mutated?, 1984 Wis. L. REv. 1679 (1984).
83. For example, a hybridoma according to Lundak's second claim did not require a separate
deposit, because the necessary starting materials were known and readily available. See supra note 36.
A hybridoma useful for production of a specific monoclonal antibody would likely require a deposit,
however, since the hybridoma would not be known or readily available. With the sophisticated and
reproducible techniques utilized in molecular biology today, a strong argument can be made for the
superfluousness of a deposit for selected inventions (for example, plasmids and peptides encoded by a
known DNA sequence), where one skilled in the art could reproduce the invention from a written
description only. In the future, an inventor might successfully file a biotechnical patent application that
does not require a deposit on the basis of constructive, rather than actual, reduction to practice. See
generally note 82.
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certain types of biological inventions. Lundak, however, has not yet obvi-
ated the legal necessity, arising out of 35 U.S.C. § 112, para. 1, for actual,
rather than constructive, reduction to practice for biological inventions that
require a deposit for enablement. 84 Therefore, Lundak will continue to have
a significant impact on procedures necessary to obtain patent protection for
certain classes of biological material, because proof of actual reduction to
practice, either through a pre-filing deposit or a post-filing deposit with
proper corroborating evidence of chain of custody, will still be required.
C. PTO Draft Policy Guidelines
The Lundak decision has prompted the PTO to draft new policy guide-
lines covering all biological deposits.8 5 As with the previous guidelines, 86
an enabling disclosure under 35 U.S.C. § 112, para. 1 may now be
satisfied either by a demonstration that a necessary biological material is
"known and readily available" to the public, or by a deposit according to
the PTO draft guidelines. 87 Reflecting Lundak, the draft guidelines require
deposit in a recognized or permanent depository "not under the control of
the depositor or patent owner," 88 prior to or at the time of payment of the
84. Inventors might benefit from the requirement for corroborating evidence that the patentable
biological material was in the inventor's hands as of the filing date. In the future the PTO could
conceivably derive essentially pre-Lundak results (deposit on or before filing) by utilizing tension
between 35 U.S.C. §§ 112 and 103 (1982). Section 103 requires that an invention be non-obvious: "A
patent may not be obtained. ., if the differences between the subject matter sought to be patented and
the prior art are such that the subject matter as a whole would have been obvious at the time the invention
was made."
If Lundak had permitted constructive reduction to practice of biological materials, reduction to
practice through a written disclosure alone by one skilled in the art might be predictable in light of prior
art. This level of predictability, in light of knowledge at the time of constructive reduction to practice,
might in turn make the invention obvious. In this context, sections 112 and 103 might be pictured as
opposite points on a continuum-the more vigorously a biological inventor argues that a deposit is not
required to provide an enabling disclosure, the more the specification will be drawn toward a section 103
rejection for obviousness.
85. Draft rules for deposit of biological materials after Lundak were released on May 2, 1986. See
Draft Guidelines, supra note 68.
86. See supra notes 2, 20.
87. Draft Guidelines, supra note 68, at 90. To provide an enabling disclosure without an accom-
panying deposit, any necessary biological material must be known and readily available to the public,
with no question of continued availability beyond the life of the patent monopoly. See id. Factors
supporting a demonstration of public accessibility, either alone or in combination, include: (1)
commercial availability of the biological material through suppliers that are not controlled by a party/
parties with an interest in the patent; (2) reference to the biological material in printed publications; (3)
declarations of accessibility to the biological material by disinterested persons in the field of the
invention; (4) abundance of the biological material in nature, either in useful form or coupled with a
reliable screening procedure; and (5) previous deposit of the biological material according to these
guidelines. See id. at 91(I.1-5).
88. Without this limitation, it would be foreseeable that large and then small biotechnology
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issue fee.89 The PTO apparently is not ready to accept continued deposit
after issuance in individual inventors' laboratories, even though certain
standards for permanence and access are met.90 By foreclosing the pos-
sibility of fulfilling the enablement requirement of section 112 through in-
house deposits after issuance, the PTO has at least avoided case by case
subjective determination of enablement, and, to the extent possible, mini-
mized the opportunity for abuse and sham.
Other proposed changes from the pre-Lundak PTO guidelines include:
(1) requirement for a viability statement;91 (2) assurance of public ac-
cessibility to the deposit for at least five years after the most recent request
for a sample, or for thirty years, whichever period is longer;92 and (3) if a
deposit is made after the filing date, a requirement for corroboration that
the biological material described in the application is the same as that
deposited in a recognized depository.93
The procedural guidelines for biological deposits drafted by the PTO
after the Lundak decision are somewhat confusing.94 If an inventor elects to
deposit in a recognized depository on or before the filing date, much of the
confusion may be avoided.
In instances of independent deposit after the filing date, the following
steps have been envisioned by the PTO. An applicant who has not placed a
necessary biological material in a recognized depository on or before the
filing date would first receive a rejection under 35 U.S.C. § 112, para. 1 for
non-enablement. The applicant could avoid the rejection either (1) by
showing that the biological material is "known and available," or (2) by
making a deposit and showing a corroborating chain of custody.95 If the
applicant takes neither of these steps, the applicant must -assure the PTO
that deposit and corroboration will be provided prior to or concurrent with
payment of the issue fee. In all instances, and as required before Lundak, an
applicant must provide the PTO access to the deposit during pendency. If
companies would develop institutional depositories which meet PTO standards. These companies could
then file for and receive patent protection strictly on the basis of in-house deposits fully within their
control.
89. The depository must be an International Depositary Authority, recognized by the Budapest
Treaty, see supra note 78, or the sample must be placed in a permanent depository that meets the
requirements of a Budapest Depository and is not controlled by the depositor or patent owner.
90. Private deposition could result in denial of public access to the patented subject matter, which
would not support the quid pro quo of the patent monopoly system.
91. Draft Guidelines, supra note 68, at 91-92(11.3). A viability statement was previously required
for deposits made under the Budapest Treaty. See supra note 78.
92. Draft Guidelines, supra note 68, at 92 (11.4).
93. 'Id. at 92 (11.5).
94. The Draft Guidelines do not expressly state what biological materials are covered. For each
biotechnical application requiring a deposit, the PTO will likely request a deposit. Before Lundak, the
PTO had the burden of making a prima facie showing of non-enablement before requiring a deposit.
95. Draft Guidelines, supra note 68, at 92.
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either assurance of deposit or deposit itself supported by corroboration is
provided, and the subject matter of the application is determined to be
patentable, the PTO will mail a notice of allowance of the patent and the
rejection for non-enablement will be withdrawn. 96 If the applicant has
neither deposited nor provided assurance of deposit before issuance, a
request for appropriate deposit under 35 U.S.C. § 132 will be issued by the
PTO.97 The applicant then has a three-month, nonextendable period in
which to deposit; otherwise the section 112 rejection will be maintained. 9 8
Although procedurally the PTO has accepted declarations of inventors in
the past, to ensure prompt public access to the invention, a notice of
allowability would be sent. The official notice of allowance could then be
reserved until the PTO has received two items: (1) documentation of an
ATCC deposit, and (2) sufficient corroborating evidence that the cell
line(s) deposited with the ATCC are identical to those in the hands of
private depositories or laboratories at the time of filing.99 The applicant
could be given three months to document independent deposit, and failure
to do so would result in final 35 U.S.C. § 112, para. 1 rejection for non-
enablement. Demanding independent deposit before mailing of a notice of
allowance would institute an objective deadline for all post-filing deposits
analogous to the pre-Lundak requirements for deposit on or before the filing
date, and would circumvent the need to subjectively review applicant's
96. Id.
97. Under section 132, if omitted requirements are found by the PTO during prosecution, the
Commissioner must notify the applicant of the requirement.
98. Reliance on personal assurances might lead to a type of "worst-possible scenario." For
instance, assume that after receipt of the PTO notice of allowance, the applicant gives assurance of
deposit and pays the required issuance fee. The patent then issues "in regular course." A deposit is now
inadvertantly made after issuance, in a situation analogous to Lundak's late filing. The courts might
have to invalidate the newly-issued claims, after the time, expense, and effort of a complete PTO
examination, because the disclosure would not be enabling upon issuance. If the PTO permitted deposit
after issuance when supported by an abundance of corroborating evidence, relying on an applicant
being in a position to deposit as of issuance, this would signal entrance to an even more dangerous
"slippery slope." Another "bright line" will be exchanged for a "slippery slope" case by case analysis,
but this time at a very real and great risk of loss to the public of benefits to be derived from the patented
invention.
Alternatively, an applicant might request a deferral of issuance under 37 C.F.R. § 1.314 (1985) upon
a showing of necessity, or might extend the three month period for independent deposit through a
process of abandonment and revival of the application under 37 C.F.R. § 1. 137 (1985) or 35 U.S.C.
§§ 133, 151 (1982). The PTO would be likely to freely permit deferrals to allow deposit before issuance,
guaranteeing public access to an enabling disclosure, but at the same time pushing back in time the 17-
year grant of a patent monopoly. The buffer zone of pendency available in Lundak would be diminished
or extinguished.
99. Deferring receipt of official PTO notice of allowance may have tax consequences for the
inventor. Prior to receipt of a notice of allowance, patent applications are assignable and nondeprecia-
ble. Upon receipt of a notice of allowance, patent applications are treated as patents, i.e., as depreciable
property under I.R.C. § 1239 (CCH 1985). See Myers v. United States, 613 F.2d 230, 205 U.S.P.Q.
(BNA) 591 (9th Cir.), cert. denied, 449 U.S. 826 (1980).
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assurances to the PTO. For many biotechnology inventors, cost/benefit
analysis and a desire for preservation of possible foreign patent rights will
limit the use of the procedure approved inLundak, at least until both United
States and foreign responses to Lundak offer more certainty to biological
inventors.
V. CONCLUSION
Prior to Lundak, the PTO required evidence of deposit in an independent
depository on or before the filing date of the patent application, but the
inventor could restrict access to the deposit until assured of patent issuance.
In Lundak, the Federal Circuit placed a stamp of approval on biological
deposits placed in recognized independent depositories after the filing date
of written patent application materials. In the wake of Lundak, an inventor
may retain control of a biological material necessary for enablement during
prosecution of the patent application. The Lundak court may have under-
estimated the possibility that inventors might abuse this retention of control
over deposits. Rather, the court viewed post-filing deposits as part of a
rational progression from restricted access to domestic and foreign inde-
pendent prefiling deposits approved inArgoudelis and Feldman. Moreover,
the Lundak court did not address the apparent conflict between post-filing
deposits and foreign filing requirements. 100
The PTO has responded to the Lundak decision with new depositing
guidelines that permit an inventor to satisfy the section 112 enablement
requirement without an independent deposit on or before the filing date.
However, the procedure described by the new PTO guidelines may insert
uncertainty into procedures for biological deposits. The danger associated
with this uncertainty is the possible loss of patent protection in instances of
post-filing deposit, due to insufficient evidence to overcome a section 112
rejection for non-enablement. The risk of sacrificing potential patent
rights, both domestic and foreign, outweighs any potential benefit derived
from depositing in an independent depository upon receipt of PTO as-
surance that patent protection is forthcoming. Therefore, the safest and
most certain course to assured enablement and subsequent issuance of a
patent is to disregard the expanded permissible deposit procedure approved
by the Federal Circuit in Lundak, and to continue to follow the depositing
procedures instituted before the Lundak decision.
Debra K. Leith
100. Perhaps the court realized that foreign patent requirements would act to moderate the practice
of depositing after the filing date, thus reducing reliance on the liberal post-Lundak procedure.
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